The State Institute for Drug Control (SÚKL) approved the clinical performance study of in vitro diagnostic device Lipidica
At the end of July, a study entitled “Clinical performance of medical device software Lipidica for processing data generated by lipidomic analysis in pancreatic cancer screening” was approved (protocol number: Lipidica_01-2024, version 1.0). The study is registered in the database ClinicalTrials.gov.
The method developed at the Faculty of Chemistry and Technology of the University of Pardubice by Professor Michal Holčapek can thus progress on its way to verification of clinical function and thus provide persons with an increased risk of developing pancreatic cancer an almost non-invasive blood test.